Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (39)

II-01

Impact of OATP1B1 Polymorphism on Pravastatin Pharmacokinetics during Pregnancy; Physiologically Based Pharmacokinetic model Prediction

Wednesday 15:35-17:00

II-02Tariq Abdulla

Using Simcyp Designer to extend a PBPK-QSP Model of Warfarin to Target Binding

Wednesday 15:35-17:00

II-14Mattia Berton

Physiologically based pharmacokinetic modelling to investigate the impact of obesity on the pharmacokinetics of rilpivirine, efavirenz, and etravirine

Wednesday 15:35-17:00

II-15Sara Bettonte

Onset and disappearance of induction on CYP3A4 and UGT1A1 substrates using PBPK modelling

Wednesday 15:35-17:00

II-21THAM THI BUI

Development of a physiological-based pharmacokinetic model for sacubitril and its metabolite

Wednesday 15:35-17:00

II-23Elisa Calvier

PBPK modelling of the DDI between a Drug X and gemfibrozil

Wednesday 15:35-17:00

II-27Marylore Chenel

Physiologically based pharmacokinetic (PBPK) modeling of the oral absorption of 5-flucytosine to support further development of a sustained-release formulation for the treatment of cryptococcal meningoencephalitis

Wednesday 15:35-17:00

II-29Brian Cicali

Long-acting formulation drug-drug interactions: evaluating the importance of timing using a subcutaneous levonorgestrel PBPK example

Wednesday 15:35-17:00

II-33Marina Cuquerella Gilabert

Title: Development of a Compartmental Advanced Physiologically based Dissolution, Absorption and Transit (CA-PhysDAT) model in PhysPK

Wednesday 15:35-17:00

II-37Neel Deferm

Development of a physiologically-based pharmacokinetic model of enzalutamide, a strong CYP3A4 inducer

Wednesday 15:35-17:00

II-38Cleo Demeester

Implementation of Oral Drug Absorption in Older Adults in the Physiologically Based Pharmacokinetic (PBPK) Modelling Platforms

Wednesday 15:35-17:00

II-39Abdallah Derbalah

Characterization of the hepatic distribution of oligonucleotide therapeutics using a cross-species biologics PBPK model

Wednesday 15:35-17:00

II-41Ilse Dubbelboer

Wednesday 15:35-17:00

II-57Berfin Gülave

P-glycoprotein mediated drug-drug interaction at the blood-brain barrier on morphine brain distribution

Wednesday 15:35-17:00

II-58Andrea Guzmán

Individualized Tacrolimus dosing in pediatric kidney transplantation: identification of new genomic, proteomic and metabolomic biomarkers and PhysPK® development of PBPK-based predictive models, simulations and applications in different phamacogenomic subpopulations.

Wednesday 15:35-17:00

II-61Sara Carolina Henriques

Development of a joint dissolution and pharmacokinetic model of propafenone and its hydroxylated metabolite

Wednesday 15:35-17:00

II-65Manuel Ibarra

Enhancing the predictive accuracy of PBPK models for drug concentrations in tissues: accounting for the impact of relative distribution of blood flow

Wednesday 15:35-17:00

II-67Nattapon Jaisupa

A physiologically-based pharmacokinetic model for prediction of cannabidiol pediatric dose

Wednesday 15:35-17:00

II-68Masoud Jamei

Application of a PBPK Model to Predict the Required Ceftazidime Concentration and Duration in Maternal and Umbilical Plasma Prior to Caesarean Section in Virtual Pregnant Women with Different Renal Function

Wednesday 15:35-17:00

III-16Christos Kaikousidis

In Silico Dosimetry Study of Tc99m-Tetrofosmin in Children Using a Novel PBPK Model in Humans Built from SPECT Imaging Data

Thursday 10:15-11:45

III-22Christina Kovar

Physiologically Based Pharmacokinetic Modeling of Dasatinib to Describe Enzyme-Mediated and pH-Dependent Drug–Drug Interaction Scenarios

Thursday 10:15-11:45

III-24Katharina Krollik

Oral absorption modeling of weakly basic drugs – Combining in vitro and in silico models

Thursday 10:15-11:45

III-27Julia Larsson

PK and PBPK modeling approaches to describe the lung and systemic exposure after inhalation of AZD4604

Thursday 10:15-11:45

III-30Maxime Le Merdy

Ocular Exposure Extrapolation Across Multiple Species Using PBPK Modeling and Simulation: Latanoprost Solution Case Study

Thursday 10:15-11:45

III-36Cong Liu

Application of translational physiologically based pharmacokinetic (PBPK) model for elucidating the complex disposition of ADCs: a case study with T-DM1

Thursday 10:15-11:45

III-37Feiyan Liu

Unravelling the effects of acute inflammation on pharmacokinetics: a model-based analysis focusing on renal excretion and CYP3A4-mediated metabolism

Thursday 10:15-11:45

III-40Helena Loer

Physiologically Based Pharmacokinetic Modeling of Imatinib and Its Main Metabolite for Drug–Drug Interaction Predictions

Thursday 10:15-11:45

III-42Orphélie Lootens

Building a physiologically-based pharmacokinetic model for a carcinogenic food contaminant aflatoxin B1

Thursday 10:15-11:45

III-54Thi Lien Ngo

Development of a Physiological-Based Pharmacokinetic Model for Ritonavir: Unraveling its Triphasic Effects as CYP3A Inhibitor, CYP3A Inducer, and Pgp Inhibitor.

Thursday 10:15-11:45

III-57Jessica Ou

Development of a physiologically-based pharmacokinetic model to understand and predict the disposition of gallium-68 radiolabeled-dendrimers in vivo

Thursday 10:15-11:45

III-59Sara Peribanez

A physiologically-based pharmacokinetic model for V937, a novel oncolytic virus, in mice

Thursday 10:15-11:45

III-61Luna Prieto Garcia

An Integrated PBPK-Quantitative Systems Pharmacology Model for Statins to Assess the Variability and Implications of Transporter-Mediated Distribution

Thursday 10:15-11:45

III-63Federico Reali

A minimal PBPK mice model to support the preclinical development of drugs against tuberculosis.

Thursday 10:15-11:45

III-64Javier Reig-López

Chirality matters: physiologically based pharmacokinetic modelling of ibuprofen enantiomers

Thursday 10:15-11:45

III-69Anuraag Saini

Development of mPBPK model to support translation decision-making for novel bispecific therapeutics

Thursday 10:15-11:45

III-70Ayatallah Saleh

Unravelling the complex inhibition network of voriconazole and its metabolites using a middle-out PBPK approach

Thursday 10:15-11:45

III-81Erik Sjögren

Mechanistic modelling of bioavailability and local immunogenicity after subcutaneous administration within the Open Systems Pharmacology framework

Thursday 10:15-11:45

III-90Cristian Valiante

PBPK model-based extrapolation from adults to children to predict furosemide oral solution bioavailability

Thursday 10:15-11:45

III-94Tan Zhang

Exploring the impact of obesity on drug clearance using PBPK modelling approaches: influential variables affecting scaling from non-obese to obese subjects for drugs metabolized in the liver

Thursday 10:15-11:45